Noble Life Sciences

Founded in 2010 by Alain Cappeluti and Kenneth Carter, Noble Life Sciences is headquartered in Gaithersburg, US.Noble Life Sciences operates as a full-service preclinical contract research organization (CRO), specializing in comprehensive solutions for drug and device development across various therapeutic areas, including oncology, infectious diseases, and diabetes. Core offerings encompass contract research and development, analytical testing, bioanalysis, pharmacodynamic modeling, and preclinical safety testing. The company serves a diverse clientele ranging from biotech firms to pharmaceutical companies, providing essential research services aimed at accelerating the transition from discovery to commercialization. Noble's preclinical services are utilized primarily in North America and Europe, facilitating advancements in cell and gene therapies, as well as innovative medical devices.Noble Life Sciences generates revenue through a B2B model, primarily engaging with pharmaceutical and biotechnology companies that require preclinical research services. Transactions typically involve contract agreements for specific research projects, with clients paying for services rendered based on established pricing structures that reflect the complexity and scope of the work. Flagship services, such as bioanalytical assays and pharmacodynamic models, are critical to the company’s revenue stream, and clients may engage Noble on a project basis or through longer-term research partnerships. These agreements are often structured to include milestone payments linked to the progression of studies, ensuring consistent financial inflow as projects advance. The company plans to introduce new bioanalytical products designed to meet emerging market needs by the end of 2024. Additionally, Noble aims to expand its operations into Europe and Asia, targeting these regions for new market opportunities within the next two years.

1. Seed

   Jan 1, 2013

   Amount

   $0.1M

   Investors

   Locked